Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
365 articles on this topic
-
Does Semaglutide Cause Dizziness? What Labels Say
Yes, dizziness can happen. The Wegovy and Ozempic labels give different levels of detail; fluid loss, blood sugar, and blood pressure help explain what a provider checks.
-
TAZPOWER Trial: What the Results Actually Show
TAZPOWER missed its main walking and fatigue goals against placebo. Longer follow-up reported gains, with enough uncertainty to require another trial.
-
Compounded Semaglutide China Alert: What It Means Now
Recent compounded semaglutide China reports trace back to two raw-ingredient factories placed on an FDA border-hold list. Here is what the alert covers, how U.S. pharmacy sourcing rules work, and what patients can ask.
-
Epitalon News Update: October 2026
July brought favorable advisory votes and a new cancer-cell study. Here is what changed for epitalon, what the FDA’s current pages say, and what remains unproven in people.
-
FDA Peptide Policy: Under Review, Not in Effect Yet
The White House logged a new FDA peptide policy notice on October 14, 2026, but the text is not public yet. Here is what the official record confirms, what unnamed sources reported about BPC-157, and what stays the same today.
-
GLP-1 Schizophrenia Study: What the Hospital Data Means
An October 2026 U.S. study linked starting a GLP-1 drug in adults with schizophrenia and type 2 diabetes to a lower psychiatric hospitalization hazard. These drugs are not FDA-approved for schizophrenia, and health records cannot prove cause and effect.
-
GLP-1 Vision Loss Study: Small Added Eye Risk Explained
October headlines revisited a 2026 diabetes study finding 3 to 4 extra coded optic-nerve cases per 10,000 people over 18 months. Here is what those numbers mean, how U.S. and European guidance differ, and why sudden vision loss needs immediate care.
-
Tirzepatide Telehealth Study: 15.5% Loss at Six Months
A large UK digital program tracked 8,127 women starting treatment, almost all on tirzepatide. Women with six-month weigh-ins lost an average of 15.5% of their starting weight, though study limits matter.
-
Relative Risk vs Absolute Risk: Numbers Explained
Relative risk compares two groups. Absolute risk shows how often an event happened. SELECT and a gallbladder warning show why both numbers matter.
-
BPC-157 for Ligaments: Animal Evidence, Human Gaps
The ligament claim comes from a rat knee study. Human trials have not shown that BPC-157 repairs an ACL tear or shortens recovery from a sprain.
-
Does Tirzepatide Cause Headaches? What Trials Show
Headaches occurred in about 7 in 100 people in SURMOUNT-1, with similar rates on placebo. Fluid loss, missed meals, and other medicines can still matter.
-
Epitalon for Sleep: Better Sleep Isn't Established
Epitalon has been studied for melatonin production, but better sleep hasn't been demonstrated in people. The small human study measured a hormone marker.
-
MOTS-c Anti Aging: Human Benefits Remain Unproven
MOTS-c has not been shown to slow aging in people. Mouse findings and human blood measurements answer narrower questions about aging.
-
Semaglutide and Smoking: Can It Help You Quit?
Early studies have found lower cigarette cravings, but semaglutide hasn't been established as a quitting treatment. The difference matters when reading the headlines.
-
MMPOWER-3 Trial: Walking and Fatigue Goals Not Met
After 24 weeks, elamipretide did not beat placebo on walking distance or fatigue. A later genetic subgroup finding led to another trial, not a new verdict.
-
Semaglutide and Testosterone: What Studies Show
Low testosterone may rise as men with obesity lose weight on semaglutide. Small studies support that link, but a direct hormone effect remains unproven.
-
Thymosin Alpha 1 Sepsis Trial: What TESTS Found
TESTS found no clear reduction in sepsis deaths: 23.4% with thymosin alpha-1 versus 24.1% with placebo. Its subgroup findings remain tentative.
-
Does Tirzepatide Cause Acid Reflux? It Can
Tirzepatide can cause reflux and indigestion. The brand labels show how often each was reported, while persistent or severe symptoms need a clinician's review.
-
Feeling Cold on Tirzepatide: An Autumn Guide
Feeling chilly can accompany weight loss, but persistent coldness deserves a closer look. Here's what the labels say and what cold weather means for storage.
-
STRIDE Trial Semaglutide: Walking Results
Semaglutide was associated with better treadmill walking in people with leg artery disease and type 2 diabetes. Here are the numbers, side effects and limits of STRIDE.
Page 1 of 19 · 365 articles